Atlas Trials

A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

Clinical trial NCT03239392 · COMPLETED

Trial details

NCT number
NCT03239392
Sponsor
Bioniz Therapeutics
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
LGL LeukemiaCTCL
Start date
2018-04-01
Primary completion
2020-06-30
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.